Goldman Sachs
EVOK

Goldman Sachs’s Evoke Pharma EVOK Stock Holding History

Goldman Sachs’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,123
Closed -$8.22K – 5724
2024
Q1 		$8.22K Buy
+1,123
New +$9.54K ﹤0.01% 5439
2021
Q1 		– Sell
-146
Closed -$54K – 6143
2020
Q4 		$54K Buy
+146
New +$75.2K ﹤0.01% 5373
2020
Q3 		– Sell
-244
Closed -$125K – 5373
2020
Q2 		$125K Buy
+244
New +$67.9K ﹤0.01% 4932

Other funds holding EVOK

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs's EVOK Position: Q2 2024 in Review

Goldman Sachs sold out of Evoke Pharma (EVOK) in Q2 2024, closing a stake of 1,123 shares — an estimated $8.22K sold.

Goldman Sachs first reported a position in EVOK in Q2 2020 and held it in 3 quarters. The position peaked at $125K in Q2 2020. 16 funds tracked by Wall St. Rank hold EVOK as of Q2 2024.

  • Goldman Sachs reported no remaining Evoke Pharma position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 1,123 Evoke Pharma shares in Q2 2024, an estimated $8.22K.
  • Goldman Sachs first reported a position in Evoke Pharma in Q2 2020 and held it in 3 quarters.
  • Goldman Sachs's Evoke Pharma position peaked at $125K in Q2 2020.
  • 16 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.